Instrument Inactif

Autres langues OUTLOOK THERAPEUTICS, INC. Nasdaq

Actions

US68235M1053

Recherche biotechnologique et médicale

Autres langues

27/08	Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026
27/08	Outlook Therapeutics Appoints Kevin Lundquist as CFO
27/08	Outlook Therapeutics, Inc. Announces Management Changes, Effective September 1, 2026
27/08	Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
27/08	Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
17/08	EyePoint's drug for age-related eye disease fails late-stage trial, shares tank
17/08	Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing
14/08	Outlook Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026
14/08	Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
13/08	Top Premarket Decliners
13/08	Outlook Therapeutics Prices $55 Million Securities Offering; Shares Down Pre-Bell
13/08	Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
12/08	Outlook Therapeutics Starts Public Offering of Stock, Warrants
12/08	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
06/08	Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
05/08	Outlook Therapeutics Secures FDA Approval For LYTENAVA™
24/07	Outlook Therapeutics Gains Following FDA Approval of Macular-Degeneration Drug -- Update
24/07	Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet Amd
24/07	Outlook Therapeutics Says Lytenava Gets FDA Approval for Retinal Disease Treatment
24/07	US FDA approves Outlook Therapeutics' eye disease drug
24/07	Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
17/07	Outlook Therapeutics Registers 17.3 Million Shares for Resale
29/06	Outlook Therapeutics Regains Nasdaq Compliance
17/06	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA as a Treatment for Wet AMD
16/06	Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application